CD200 and medulloblastoma: The same trend may be true for ependymoma and medulloblastoma subsets, posterior fossa A and group 3 (cMYC+) subgroups, respectively, which are more aggressive, have low CD200 expression and exhibit high immune infiltrates [19,30,31].